ArticleFrontiers in aging neuroscience2025
Elevated monocyte-to-high-density lipoprotein ratio is associated with increased risk of cognitive impairment and severe cerebral small vessel disease burden.
Article in Frontiers in aging neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Age-associated chemokine receptor expression profiles in human peripheral blood monocyte subsets predict cardiovascular disease risk.Frontiers in immunology · 2026Article
- Association between the monocyte-to-high-density lipoprotein cholesterol ratio and abdominal aortic calcification in adults: Insights from the National Health and Nutrition Examination Survey (2013-2014).The Journal of international medical research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Monocyte-to-high-density lipoprotein ratio (MHR), as a novel biomarker, has shown potential in predicting the onset and progression of various diseases. However, the relationship between MHR and cerebral small vessel disease (CSVD) as well as cognitive impairment (CI), which are inflammation-related conditions remains unclear. This research explores the relationship between MHR and total CSVD burden as well as CI. Methods: This retrospective analysis included 212 eligible patients. On the basis of Mini-Mental State Examination (MMSE) scores, patients were classified into CI and no CI groups. Total CSVD burden was assessed using a composite score incorporating four MRI-based imaging markers. Participants were further stratified into mild and severe CSVD burden groups. MHR was determined by dividing the blood monocyte count by the high-density lipoprotein (HDL) concentration. Statistical analyses, including logistic regression, trend tests, restricted cubic spline modeling, and mediation analysis, were conducted using SPSS 26.0 and R software to explore the associations of MHR with CI, and CSVD burden. Results: Non-parametric analysis revealed that patients with CI and those with severe CSVD burden exhibited significantly higher MHR levels ( Conclusion: Elevated MHR is related to increased CSVD burden and CI. The mediating roles of severe CSVD burden indicates that a high MHR level may contribute to the progression of CSVD, thereby elevating the risk of CI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.